Brief: CEL-SCI’s Multikine Phase 3 Cancer Study Shows 43% Survival Extension

CEL-SCI

08/03/2023 15:12

March 8 (Reuters) - CEL-SCI Corp  CVM.A :
    * CEL-SCI’S MULTIKINE PHASE 3 CANCER STUDY SHOWS 43%
SURVIVAL
EXTENSION
    * CEL-SCI CORP- PLANS TO SUBMIT BLA TO U.S. FDA AND OTHER
REGULATORY AGENCIES FOR APPROVAL OF MULTIKINE IN TREATMENT OF
NEWLY DIAGNOSED SCCHN

Source text for Eikon:  ID:nBw1LDlsva 
Further company coverage:  CVM.A